索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]孙玉,郭守玉,龙明智.维利西呱治疗慢性心力衰竭的研究进展[J].国际心血管病杂志,2023,02:78-80.
点击复制

维利西呱治疗慢性心力衰竭的研究进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2023年02期
页码:
78-80
栏目:
综述
出版日期:
2023-03-20

文章信息/Info

Title:
-
作者:
孙玉; 郭守玉; 龙明智
210000 南京医科大学第二附属医院心血管内科
Author(s):
-
关键词:
可溶性鸟苷酸环化酶; 维利西呱; 慢性心力衰竭
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2023.02.004
文献标识码:
-
摘要:
慢性心力衰竭是各种心血管疾病的终末表现及主要死因，除了经典的神经内分泌阻滞药物，还有对其他靶点进行干预的药物。可溶性鸟苷酸环化酶激动剂维利西呱可通过作用于一氧化氮- 可溶性鸟苷酸环化酶- 环鸟苷酸通路，治疗慢性心力衰竭。该文介绍维利西呱的作用机制和相关临床试验进展。
Abstract:
-

参考文献/References

[1] Bozkurt B, Coats AJ, Tsutsui H, et al. Universal definitionand classification of heart failure: a report of the Heart FailureSociety of America, Heart Failure Association of the EuropeanSociety of Cardiology, Japanese Heart Failure Society andWriting Committee of the Universal Definition of HeartFailure[J]. J Card Fail, 2021:S1071-9164(21)00050-6.
[2] McDonagh TA, Metra M, Adamo M, et al. 2021 ESCguidelines for the diagnosis and treatment of acute and chronicheart failure[J]. Eur Heart J, 2021, 42(36):3599-3726.
[3] Bonderman D, Ghio S, Felix SB, et al. Riociguat forpatients with pulmonary hypertension caused by systolicleft ventricular dysfunction: a phase Ⅱb double-blind,randomized, placebo-controlled, dose-ranging hemodynamicstudy[J]. Circulation, 2013, 128(5):502-511.
[4] Bonderman D, Pretsch I, Steringer-Mascherbauer R, et al.Acute hemodynamic effects of riociguat in patients withpulmonary hypertension associated with diastolic heart failure(DILATE-1): a randomized, double-blind, placebo-controlled,single-dose study[J]. Chest, 2014, 146(5):1274-1285.
[5] 中华医学会老年医学分会心血管疾病学组, 《老年慢性心力衰竭诊治中国专家共识》编写组. 老年人慢性心力衰竭诊治中国专家共识(2021)[J]. 中华老年医学杂志, 2021,40(5):550-561.
[6] 夏晓东, 徐正衸. 可溶性鸟苷酸环化酶及其调节[J]. 国外医学(生理、病理科学与临床分册), 2003, 23(4):396-399．
[7] Aimo A, Castiglione V, Vergaro G, et al. The place of vericiguatin the landscape of treatment for heart failure with reducedejection fraction[J]. Heart Fail Rev, 2022, 27(4):1165-1171.
[8] Friebe A, Sandner P, Schmidtko A. cGMP: a unique 2ndmessenger molecule—recent developments in cGMP researchand development[J]. Naunyn Schmiedebergs Arch Pharmacol,2020, 393(2):287-302.
[9] Blanton RM. cGMP signaling and modulation in heartfailure[J]. J Cardiovasc Pharmacol, 2020, 75(5):385-398.
[10] Dasgupta A, Bowman L, D’Arsigny CL, et al. Solubleguanylate cyclase: a new therapeutic target for pulmonaryarterial hypertension and chronic thromboembolic pulmonaryhypertension[J]. Clin Pharmacol Ther, 2015, 97(1):88-102.
[11] Boettcher M, Gerisch M, Lobmeyer M, et al. Metabolism andpharmacokinetic drug-drug interaction profile of vericiguat, asoluble guanylate cyclase stimulator: results from preclinicaland phaseⅠhealthy volunteer studies[J]. Clin Pharmacokinet,2020, 59(11):1407-1418.
[12] Shea CM, Price GM, Liu G, et al. Soluble guanylate cyclasestimulator praliciguat attenuates inflammation, fibrosis, andend-organ damage in the Dahl model of cardiorenal failure[J].Am J Physiol Renal Physiol, 2020, 318(1):F148-F159.
[13] Hulot JS, Trochu JN, Donal E, et al. Vericiguat for thetreatment of heart failure: mechanism of action andpharmacological properties compared with other emergingtherapeutic options[J]. Expert Opin Pharmacother, 2021,22(14):1847-1855.
[14] Coats AJ. Vericiguat for heart failure and the Victoria trial—the dog that didn’t bark?[J]. Eur J Heart Fail, 2020, 22(4):576-577.
[15] Gheorghiade M, Greene SJ, Butler J, et al. Effect of vericiguat,a soluble guanylate cyclase stimulator, on natriuretic peptidelevels in patients with worsening chronic heart failure andreduced ejection fraction: the SOCRATES-REDUCEDrandomized trial[J]. JAMA, 2015, 314(21):2251-2262.
[16] Kramer F, Voss S, Roessig L, et al. Evaluation of highsensitivityC-reactive protein and uric acid in vericiguattreatedpatients with heart failure with reduced ejectionfraction[J]. Eur J Heart Fail, 2020, 22(9):1675-1683.
[17] Armstrong PW, Roessig L, Patel MJ, et al. A multicenter,randomized, double-blind, placebo-controlled trial of theefficacy and safety of the oral soluble guanylate cyclasestimulator: the VICTORIA trial[J]. JACC Heart Fail, 2018,6(2):96-104.
[18] Pieske B, Maggioni AP, Lam CSP, et al. Vericiguat inpatients with worsening chronic heart failure and preservedejection fraction: results of the SOluble guanylate CyclasestimulatoR in heArT failurE patientS with PRESERVED EF(SOCRATES-PRESERVED) study[J]. Eur Heart J, 2017,38(15):1119-1127.
[19] Armstrong PW, Lam CSP, Anstrom KJ, et al. Effect ofvericiguat vs placebo on quality of life in patients with heartfailure and preserved ejection fraction: the VITALITY-HFpEFrandomized clinical trial[J]. JAMA, 2020, 324(15):1512-1521.
[20] Butler J, Lam CSP, Anstrom KJ, et al. Rationale and designof the VITALITY-HFpEF trial[J]. Circ Heart Fail, 2019,12(5):e005998.
[21] Krishnan SM, Kraehling JR, Eitner F, et al. The impactof the nitric oxide (NO)/soluble guanylyl cyclase (sGC)signaling cascade on kidney health and disease: a preclinicalperspective[J]. Int J Mol Sci, 2018, 19(6):1712.

备注/Memo

备注/Memo:
通信作者：龙明智， E-mail：longmzh@hotmail.com
更新日期/Last Update: 2023-03-20